Clinical Trial Update: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial sponsored by Stanford University is evaluating anti-CD19 CAR-T cell therapy for non-relapsing and progressive forms of multiple scleros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis

Drugs mentioned

• Anti-CD19 CAR-T cell therapy (CD19-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Stanford University | Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | Phase 1 | Status: RECRUITING